Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …
Biogen’s Alzheimer’s disease drug Aduhelm has endured a headache of a launch, largely due to lingering questions about its true clinical benefit and how the …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
